公开(公告)号：EP2573114A1

公开(公告)日：2013-03-27

申请号：EP12171813.4

申请日：2006-08-10

申请人： MacroGenics, Inc.

发明人： Stavenhagen, Jeffery ,  Gorlatov, Sergey ,  Rankin, Christopher ,  Tuaillon, Nadine

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C12N5/00 ,  C12N15/00 ,  C12Q1/68 ,  C07K17/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/44 ,  G01N33/574

CPC分类号： G01N33/574 ,  A61K2039/505 ,  C07K16/283 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g. , cancer, infections disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

摘要翻译： 本发明涉及一种分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），包含变体Fc区，worin所述变体Fc区的至少一个氨基酸相对于野生型Fc区修饰，该变体Fc区包含 结合Fc³RIIIA和/或与Fc³RIIA更大的亲和力，相对于可比分子包含野生型Fc区。 本发明的分子在预防，治疗或改善与疾病，病症或感染相关的一种或多种症状是特别有用的。 本发明的分子可用于疾病或病症，其中增强由Fc³R介导的效应细胞功能（例如，ADCC）的功效期望的治疗或预防特别有用，E.G. ，癌症，感染性疾病，和在提高的治疗性抗体的治疗功效的所有其通过ADCC介导的效果。

公开(公告)号：EP2573114B1

公开(公告)日：2016-03-30

申请号：EP12171813.4

申请日：2006-08-10

申请人： MacroGenics, Inc.

发明人： Stavenhagen, Jeffery ,  Gorlatov, Sergey ,  Rankin, Christopher ,  Tuaillon, Nadine

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C12N15/00 ,  C12Q1/68 ,  C07K17/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/44 ,  G01N33/574 ,  A61K39/00

CPC分类号： G01N33/574 ,  A61K2039/505 ,  C07K16/283 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc³RIIIA and/or Fc³RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc³R is desired, e.g. , cancer, infections disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.